What are you searching for?

Sign in
Breaking News

GC Biopharma Establishes mRNA Production Facility in Korea

GMP pilot plant will support the company's strategy to internalize various mRNA-related technologies.

GC Biopharma has completed the construction of an mRNA (messenger ribonucleic acid) production facility at its vaccine production plant in Hwasun, Jeollanam-do, Korea. The GMP facility will support the company’s strategy to internalize various mRNA-related technologies and capabilities.

 
The new facility offers production capabilities that accommodates all phases of mRNA production, reducing the contamination risk of transfer and allowing prompt production response. The pilot plant leverages single-use technology and enables the production of multiple products at once.
 
Last year GC Biopharma signed a lipid nanoparticle (LNP) development and option agreement with Acuitas Therapeutics that resulted in establishing a new mRNA-LNP platform. The company is now actively advancing this platform into clinical stage development for a treatment for Succinic semialdehyde dehydrogenase deficiency (SSADH), a rare disorder that causes neurological problems, as well as an mRNA influenza vaccine.

With the technologies and capabilities of new mRNA production facility, GC Biopharma can test the safety and efficacy of various vaccines and drug candidates, with future plans to produce drugs for clinical trials and commercialization to further the CMO business.
 
Jae Uk Jeong, head of R&D at GC Biopharma said, “Construction of the new production facility was a part of our project to move ahead in securing mRNA platform technology. We expect the facility to be widely used in joint R&D projects and responses to any future pandemics.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics